Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · IEX Real-Time Price · USD
3.090
-0.130 (-4.04%)
At close: Jul 19, 2024, 4:30 PM
3.080
-0.010 (-0.32%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.
Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | David A. Happel |
Contact Details
Address: 155 Bovet Rd., Suite 303 San Mateo, California 94402 United States | |
| Phone | (650) 561-8600 |
| Website | sagimet.com |
Stock Details
| Ticker Symbol | SGMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001400118 |
| CUSIP Number | 786700104 |
| ISIN Number | US7867001049 |
| Employer ID | 20-5991472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Happel | Chief Executive Officer, President and Director |
| Dr. George W. Kemble Ph.D. | Executive Chairman of the Board |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer |
| Urs Greber Ph.D. | Co-Founder |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder |
| Joe Oriti | Interim Principal Financial Officer and Interim Principal Accounting Officer |
| Elizabeth Rozek Esq., J.D. | General Counsel and Chief Compliance Officer |
| Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K/A | [Amend] Current report |
| Jun 6, 2024 | 8-K | Current Report |
| May 23, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | 8-K | Current Report |
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |